Supernus Pharmaceuticals PE ratio SUPN

Share price divided by earnings per share over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 47.9×; Oct 2025
10-year median: 23.8×
10-year range: 7.5× to 391×
Peer median: 15.7×

Supernus Pharmaceuticals has no meaningful PE ratio today: it lost $1.92 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Oct 2025, at 47.9×.

On the days it had one over the last ten years, its median was 23.8×, from 7.5× in Mar 2020 to 391× in Aug 2024.

PE ratio over time

median 23.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	47.9×	23.3×	47.9×
2024	34.7×	33.1×	391×
2023	72.3×	32.7×	73.1×
2022	55.7×	19.6×	58.6×
2021	19.3×	10.4×	22.2×
2020	10.4×	7.5×	12.4×
2019	12.0×	11.0×	21.3×
2018	17.6×	16.8×	45.8×
2017	37.6×	16.0×	56.0×
2016	52.6×	37.2×	67.3×
2015	58.4×	22.3×	72.4×

Against its peers

Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first, today.

Company	PE ratio
SUPNSupernus Pharmaceuticals	n/m
PBHPrestige Consumer Healthcare	13.4×
HRMYHarmony Biosciences	11.7×
NRIXNurix Therapeutics	11.0×
ANIPANI Pharmaceuticals	15.4×
PAHCPhibro Animal Health	15.9×
OGNOrganon	17.9×
LQDALiquidia	30.7×
ANABAnaptysbio	10.7×
PCRXPacira BioSciences	104×
ARQTArcutis Biotherapeutics	142×
Peer median	15.7×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Supernus Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.